+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 19 Actively Recruiting clinical trials

G

Actively Recruiting

Researchers are evaluating volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma LA-HNSCC who have not experienced disease progression after completing definitive concurrent chemoradiotherapy cCRT. This Phase III study aims to assess the efficacy and safety of volrustomig as a sequential therapy following standard treatment in this patient group. Participants are randomly assigned to one of two groups one group receives volrustomig, while the other undergoes observation without additional treatment. The study is open-label and conducted globally, with the treatment and observation phases occurring after completion of prior chemoradiotherapy. The study period extends up to approximately 8 years to monitor long-term outcomes. During the study, participants will be regularly assessed for progression-free survival, overall survival, and physical functioning, among other measures. Blood samples will be collected to evaluate the presence of anti-drug antibodies and drug pharmacokinetics. Quality of life questionnaires and safety monitoring for adverse events will also be conducted. Participants may be followed for up to 8 years after starting the study to track these outcomes.

Age: 18Years - 130YearsAll GendersPhase 3
306 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Datopotamab Deruxtecan Dato-DXd with or without durvalumab compared to chemotherapy chosen by doctors combined with pembrolizumab in people with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer TNBC. This Phase III international study aims to see if Dato-DXd plus durvalumab can help patients live longer without their cancer worsening or improve overall survival, while also assessing impacts on quality of life. Participants are randomly assigned to one of three groups Dato-DXd with durvalumab, a chemotherapy option paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin combined with pembrolizumab, or Dato-DXd alone. All study drugs are given by intravenous infusion. The study will monitor patients for disease progression and response, with treatments and evaluations continuing for up to about 33 months. During the study, participants will undergo regular assessments including tumor measurements by imaging using RECIST 1.1 criteria, survival tracking, and quality of life evaluations focused on symptoms like breast and arm pain and physical functioning. Safety and drug effects will also be closely monitored throughout treatment and follow-up. The total study participation may last several years, with some outcomes measured up to 64 months from randomization.

Age: 18Years +All GendersPhase 3
318 locations
E

Actively Recruiting

Researchers are evaluating treatments for patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer that is locally advanced or metastatic. This phase III, global, randomized, open-label study compares the effectiveness and safety of inavolisib combined with fulvestrant versus alpelisib combined with fulvestrant. Participants have experienced disease progression during or after therapy with cyclin dependent kinase 46 inhibitors combined with endocrine therapy. Participants receive study drugs in repeated 28-day cycles. Inavolisib is taken orally once daily at 9 mg on days 1 to 28 of each cycle, while fulvestrant is administered at 500 mg on days 1 and 15 of the first cycle and day 1 of subsequent cycles. The comparator group receives alpelisib at 300 mg orally once daily plus fulvestrant on the same schedule. A substudy evaluates the effect of inavolisib plus fulvestrant on the metabolism of certain enzyme substrates by administering midazolam, omeprazole, and bupropion on specified days within the first cycle. Participants undergo regular assessments including tumor evaluations per RECIST criteria, blood tests, and monitoring of drug levels. The primary outcome measures progression-free survival assessed by independent review up to approximately 64 months. Secondary outcomes include overall survival, response rates, quality of life, and safety events monitored up to about 85 months. The study includes frequent visits during treatment cycles and follow-ups to evaluate side effects and long-term outcomes.

Age: 18Years +All GendersPhase 3
210 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.

Age: 18Years +All GendersPhase 3
317 locations
R

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of SPT-300 GlyphAllo, a prodrug of allopregnanolone, in adults aged 18 to 65 years with major depressive disorder MDD, including those with or without anxious distress. This Phase 2 randomized, double-blind, placebo-controlled study aims to better understand how SPT-300 impacts depressive symptoms compared to placebo. Participants will be randomly assigned to receive either SPT-300 capsules or a matching placebo once daily for 42 days. The study is designed as a parallel-group trial with two arms one receiving the experimental drug SPT-300 and the other receiving placebo. Treatment effects will be closely monitored during this 6-week period. Throughout the study, participants will undergo assessments including the Hamilton Depression Rating Scale-17 HAM-D-17 and the Clinical Global Impression - Severity CGI-S to measure changes in depressive symptoms from baseline to day 42. Safety and tolerability will also be evaluated. The total participation duration extends until study completion in March 2027, with regular visits to monitor progress and well-being.

Age: 18Years - 65YearsAll GendersPhase 2
61 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness of osavampator compared to a placebo as an additional treatment to delay the return of depressive symptoms in adults with major depressive disorder MDD. This Phase 3 study focuses on maintaining treatment effects in participants diagnosed with recurrent moderate or severe MDD or persistent depressive disorder who have not responded adequately to oral antidepressants. The study aims to understand whether osavampator can help prevent relapse in this population. Participants will first receive osavampator during an initial open-label treatment phase. Following this, they will be randomly assigned to receive either osavampator or a matching placebo during a double-blind maintenance period. Both treatments are given as oral tablets, and participants will continue their existing oral antidepressants at the same dose and frequency throughout the study. The study may last up to approximately 32 months from randomization. During the study, participants will be regularly monitored for relapse of depressive symptoms using the Hamilton Depression Rating Scale. Researchers will track the time from randomization to relapse or the end of the study to assess treatment maintenance. Safety and adherence will be evaluated throughout, with participants expected to comply with study procedures and restrictions. The total duration of participation varies but can extend up to nearly three years.

Age: 18Years +All GendersPhase 3
61 locations
R

Actively Recruiting

Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.

Age: 18Years +All GendersPhase 3
447 locations
O

Actively Recruiting

Researchers are evaluating the safety and effectiveness of BGB-43395 combined with letrozole compared to a choice of approved cyclin-dependent kinase 46 inhibitors abemaciclib, palbociclib, or ribociclib combined with letrozole in adults with advanced or metastatic hormone receptor positive HR and human epidermal growth factor receptor 2 negative HER2- breast cancer. The study focuses on patients who have not previously received systemic treatment for advanced or metastatic disease. This phase 3 trial aims to provide insight into treatment options for this patient group. Participants are randomly assigned to one of two groups one receiving BGB-43395 plus letrozole, and the other receiving an investigators choice of CDK46 inhibitor abemaciclib, palbociclib, or ribociclib plus letrozole. All medications are taken orally. The study compares these treatment combinations over a period lasting up to approximately 4 years for primary outcomes, with longer follow-up for secondary outcomes. During the trial, participants will be regularly monitored for disease progression, response to treatment, overall survival, and safety through various assessments. These include evaluations of progression-free survival by independent review, overall response rate, duration of response, clinical benefit rate, and adverse events. Quality of life measures and other clinical outcomes are also tracked. Participant involvement may last up to 11 years to capture long-term effects and safety.

Age: 18Years +All GendersPhase 3
241 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of SPN-821, a novel oral drug, as an additional treatment for adults with major depressive disorder MDD. This phase 2, multicenter, randomized, double-blind, placebo-controlled study focuses on adults diagnosed with MDD who continue to experience symptoms despite stable antidepressant therapy. The study aims to assess improvements in depression severity using standardized rating scales. Participants are randomly assigned to receive either SPN-821 at a dose of 2400 mg three 800 mg tablets or matching placebo tablets, both administered twice a week alongside their current antidepressant medication. The study includes a 2-week screening period to confirm eligibility, followed by a 4-week treatment period where participants receive the assigned study tablets. After completing treatment, participants undergo a safety follow-up phone call one week later to monitor any ongoing effects. During the study, participants will have their depression symptoms evaluated using the Montgomery-sberg Depression Rating Scale MADRS and Clinical Global Impression-Severity CGI-S scale at baseline and Day 29. Safety assessments and monitoring occur throughout the trial and during the follow-up call. Overall, the study participation lasts approximately 7 weeks including screening, treatment, and follow-up to understand the impact of SPN-821 on depressive symptoms and safety in adults with MDD.

Age: 18Years - 70YearsAll GendersPhase 2
40 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ficerafusp alfa combined with pembrolizumab compared to placebo with pembrolizumab in adults with first-line PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma HNSCC. This study targets two cancer drivers, EGFR and TGF-beta, to address tumor growth and spread. It includes phase 2 to find the best dose and phase 3 to compare treatment outcomes. In phase 2, participants are randomly assigned to one of three groups ficerafusp alfa 1500 mg weekly plus pembrolizumab every three weeks, ficerafusp alfa 750 mg weekly plus pembrolizumab every three weeks, or placebo weekly plus pembrolizumab every three weeks. Phase 3 uses the optimal dose of ficerafusp alfa with pembrolizumab versus placebo with pembrolizumab in a 21 ratio. Treatments continue with scheduled dosing during each phase. Participants undergo regular assessments including scans to measure tumor response by RECIST 1.1 criteria, safety monitoring for side effects, and quality of life questionnaires. The study tracks objective response rate, overall survival, progression-free survival, and other measures over up to three years. Safety is closely monitored for treatment-related adverse events during and after therapy. Total participation may last several years depending on treatment and follow-up.

Age: 18Years +All GendersPhase 2Phase 3
231 locations

1-10 of 19

1